Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
December 10, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Kuehn Law Encourages BRKH, CDMO, EMKR, and CTV Investors to Contact Law Firm
December 04, 2024 09:07 ET
|
KUEHN LAW, PLLC
Kuehn Law Encourages BRKH, CDMO, EMKR, and CTV Investors to Contact Law Firm
Kuehn Law Encourages AVAV, AE, CDMO, and ALTR Investors to Contact Law Firm
November 21, 2024 09:03 ET
|
KUEHN LAW, PLLC
Kuehn Law Encourages AVAV, AE, CDMO, and ALTR Investors to Contact Law Firm
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
September 12, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
September 09, 2024 16:05 ET
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
September 03, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
July 02, 2024 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
July 01, 2024 07:00 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
May 23, 2024 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Participate at Upcoming Investor Conferences
May 07, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...